Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
TKIs may be a more optimal drug sequence than DurTre after AteBev treatment from an oncological perspective. TKIs following AteBev treatment require careful monitoring for deteriorating liver function.
Authors
- Takanori Matsuura (ORCID: https://orcid.org/0009-0008-7361-881X)
- Keisuke Arai (ORCID: https://orcid.org/0000-0001-8849-9720)
- SHOHEI KOMATSU
- Hirochika Toyama (ORCID: https://orcid.org/0000-0003-0360-8460)
- Hiroaki Yanagimoto (ORCID: https://orcid.org/0000-0001-6493-4732)
- Jun Ishida (ORCID: https://orcid.org/0000-0001-7550-448X)
- TOSHIFUMI TADA
- Nobuaki Ishihara
- KENTARO TAI (ORCID: https://orcid.org/0000-0003-2372-4100)
- Takeshi Urade (ORCID: https://orcid.org/0000-0002-4557-1777)
- Takumi Fukumoto
- Hidetoshi Gon (ORCID: https://orcid.org/0000-0002-4338-6084)
- Yoshihiko Yano (ORCID: https://orcid.org/0000-0002-5177-7480)
- Yuzo Kodama (ORCID: https://orcid.org/0000-0002-1741-5638)
- Kenji Fukushima (ORCID: https://orcid.org/0000-0003-2844-2284)
- Toshihiko Yoshida
- Yoshimi Fujishima
- Masahiro Kido
Institutions
- Kobe Medical Center (JP)
- Kobe University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.21873/anticanres.17412
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.74